Mesoblast Reaches Full Enrollment in Phase 3 Trial for Chronic Low Back Pain Therapy
Mesoblast Limited (ASX: MSB) has completed patient recruitment for its pivotal Phase 3 study of rexlemestrocel-L, a cell-based therapy targeting chronic low back pain linked to degenerative disc disease. The trial will monitor more than 300 participants over a 12-month period, comparing a single intra-discal injection against a control to evaluate reductions in pain and improvements in daily function. The study builds on earlier clinical outcomes that showed meaningful and sustained pain relief along with reduced reliance on opioid medications. Key endpoints include pain reduction, functional outcomes, and quality of life measures. The company expects initial results around mid-2027, which could support a regulatory submission to the U.S. Food and Drug Administration later that year. With RMAT designation already granted, the therapy may benefit from an expedited review process, reinforcing its potential as a novel non-opioid treatment option.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Mesoblast Reaches Full Enrollment in Phase 3 Trial for Chronic Low Back Pain Therapy
Mesoblast Limited (ASX: MSB) has completed patient recruitment for its pivotal Phase 3 study of rexlemestrocel-L, a cell-based therapy targeting chronic low back pain linked to degenerative disc disease. The trial will monitor more than 300 participants over a 12-month period, comparing a single intra-discal injection against a control to evaluate reductions in pain and improvements in daily function. The study builds on earlier clinical outcomes that showed meaningful and sustained pain relief along with reduced reliance on opioid medications. Key endpoints include pain reduction, functional outcomes, and quality of life measures. The company expects initial results around mid-2027, which could support a regulatory submission to the U.S. Food and Drug Administration later that year. With RMAT designation already granted, the therapy may benefit from an expedited review process, reinforcing its potential as a novel non-opioid treatment option.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au